GlassScriptPhysician profile
Sherif E Elhanafi
NPI 1619237534
$7,368.05
in general payments reported to CMS, 2019-2025
23 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $2,029 · 2021: $580 · 2022: $659 · 2023: $1,099 · 2024: $748 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,838 · Travel and Lodging: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.09 |
| Travel and Lodging | $702.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,821.24 | 2020-2023 | Exalt Model D |
| Abbvie INC. | $915.12 | 2024-2025 | |
| Endogastric Solutions, INC | $677.25 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $525.69 | 2021-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $507.22 | 2019-2025 | Xifaxan |
| Ovesco Endoscopy USA, INC. | $415.86 | 2023 | |
| Medtronic, INC. | $351.63 | 2021-2025 | Concertotm, Pillcam |
| Phathom Pharmaceuticals, INC. | $289.14 | 2024 | Voquezna |
| Pfizer INC. | $246.35 | 2019-2024 | |
| Gilead Sciences, INC. | $242.18 | 2019-2025 | |
| Ardelyx, INC. | $206.31 | 2025 | Ibsrela |
| Enterra Medical, INC. | $160.04 | 2025 | |
| Madrigal Pharmaceuticals | $156.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Olympus America INC. | $150.42 | 2019-2025 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope, Olympus |
| Merit Medical Systems INC | $140.28 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $133.51 | 2020-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $115.38 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $97.41 | 2022 | |
| Ambu INC. | $53.61 | 2021 | |
| Lumendi LLC | $51.61 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $46.47 | 2025 | Dupixent |
| Janssen Biotech, INC. | $44.84 | 2025 | Tremfya |
| Covidien LP | $20.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherif Elhanafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.